Log in  First Connection?

MelanomaArchives

CAR-T cell immunotherapy of malignant melanoma
Melanoma
 1 min.

 Published on 09/02/2026 |  Original article (Full-text)  | Olha Kharasakhal et al. | Expert Review of Clinical Immunology 2026; aop:10.1080/1744666X.2026.2621811

Management of inoperable and advanced malignant melanoma has been transformed in recent years by the advent of a number of approaches, including immune checkpoint blockade, small-molecule inhibitors, and adoptive immunotherapy with ex vivo expanded tumor-infiltrating lymphocytes. In this review, we describe...

The role of transcription factor TBX19 in melanoma: a comprehensive bioinformatics analysis and cellular experiments
Melanoma
 6 min.

 Published on 02/02/2026 |  Original article (Full-text)  | Yuan Bing et al. | BMC Cancer 2025; 26(1): 162

Skin cutaneous melanoma (SKCM) is a highly aggressive form of skin cancer originating from melanocytes. Its global incidence has risen steadily, with an estimated 325,000 new cases and over 57,000 deaths in 2020, according to the World Health Organization, posing a significant public health challenge...

Risk of malignant melanoma and colorectal cancer in Birt-Hogg-Dubé syndrome – a matched cohort study
Melanoma
 4 min.

 Published on 26/01/2026 |  Original article (Full-text)  | Skarin Nordenvall Anna et al. | British Journal of Cancer 2026; 134(2): 245-51

Birt-Hogg-Dubé syndrome (BHDS) (OMIM#135150) is a rare autosomal dominant tumor-predisposition syndrome caused by pathogenic variants in the FLCN gene encoding the folliculin protein which has been implicated in the regulation of cellular survival, proliferation, and growth by interacting...

A prognostic model for uveal melanoma in Asian populations: a comparative analysis of clinical features and gene expression patterns using the TRACE and TCGA data
Melanoma
 5 min.

 Published on 19/01/2026 |  Original article (Full-text)  | Luo Jingting et al. | BMC Ophthalmology 2025; 26(1): 8

Uveal melanoma (UM) is the most common primary intraocular malignancy in adults [1]. Despite advances in primary tumor treatment, survival rates have not improved, largely due to early subclinical micrometastasis at early stages [2]. Recently, Tebentafusp became the first drug showing a survival benefit...

Research hotspots and trends of immunotherapy and melanoma: A bibliometric analysis during 2014–2024
Melanoma
 1 min.

 Published on 12/01/2026 |  Original article (Full-text)  | Zixuan Jia et al. | Human vaccines & immunotherapeutics 2025; 21(1):

Over the last decade, the increasing global prevalence of melanoma has sparked growing interest in immunotherapies, which show significant potential against this form of skin cancer. This research aims to offer a framework to guide future studies and inspire new research directions. In this study, we...